Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera

Molecular Biology Reports

Volumn 39, Issue 9, 2012, Pages 8663-8667

  Karkucak, Mutlu ^a   Yakut, Tahsin ^a   Ozkocaman, Vildan ^a   Ozkalemkas, Fahir ^a   Ali, Ridvan ^a   Bayram, Murat ^a   Gorukmez, Orhan ^a   Ocakoglu, Gokhan ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Essential thrombocythemia; JAK2; Polycythemia vera

Indexed keywords

HEMOGLOBIN;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAK2 V617F GENE; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA VERA; POPULATION RESEARCH; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TURKISH;

ADULT; AGED; FEMALE; GENOTYPE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, ESSENTIAL; TURKEY;

TETRA;

EID: 84865147431     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1721-x     Document Type: Article

References (24)

1. Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6:372-375
2. Lieu CH, Wu HS, Hon YC et al (2008) Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Intern Med J. 38:422-426 (Pubitemid 351871971)
3. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302
4. James C, Ugo V, LeCouedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434:1144-1148 (Pubitemid 40663494)
5. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397 (Pubitemid 40544655)
6. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790 (Pubitemid 40570926)
7. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 365:1054-1061 (Pubitemid 40386783)
8. Er TK, Lin SF, Chang JG et al (2009) Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. Clin Chim Acta 408:39-44
9. Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355:2452-2466 (Pubitemid 44903749)
10. Jones AV, Kreil S, Zoi K et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168 (Pubitemid 41291734)
11. Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945-1953 (Pubitemid 41713984)
12. Antonioli E, Guglielmelli P, Pancrazzi A et al (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19:1847-1849 (Pubitemid 41486170)
13. Wadleigh M, Tefferi A (2010) Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 91:174-179
14. Koksal V, Etlik O, Arican-Baris ST, Baris I (2007) A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation. Genet Test 11:463-466
15. Langabeer SE, Ni Ainle F, Conneally E, Lawler M (2007) Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Ir J Med Sci 176:105-109 (Pubitemid 46952281)
16. Shen YM, Chao HY, Zhang R et al (2009) Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders. J Int Med Res 37:37-46
17. Basquiera AL, Soria NW, Ryser R et al (2009) Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology 2009(14):323-330
18. Zhao R, Xing S, Li Z, Li Q, Krantz SB, Zhao ZJ (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788-22792 (Pubitemid 40853184)
19. Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi S (2011) JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. Pathol Biol. 59:e89-e92
20. Zhang SJ, Li WD, Song JH, Xu W, Qiu HX, Li JY (2007) The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis. Zhonghua Yi Xue Za Zhi 87:2109-2112 (Pubitemid 350019943)
21. Wong GC, Kam GL, Koay ES (2010). JAK2 mutations in Asian patients with essential thrombocythaemia. Intern Med J. doi: 10.1111/j.1445-5994.2010.02199.x
22. Tefferi A, Lasho TL, Schwager SM et al (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. Cancer 106:631-636 (Pubitemid 43157627)
23. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prehal JT, Verstovsek S (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Phledelphia chromosome negative CML, and megakaryocytic leukemia. Blood 106:3370-3373 (Pubitemid 41609167)
24. Moliterno AR, Donna MW, Ophelia R, Spivak JL (2006) Moleculer mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108:3913-3915 (Pubitemid 44864576)